Male infertility (non-obstructive azoospermia) Cell Models for Research

Male infertility affects approximately 7% of men globally, with non-obstructive azoospermia (NOA) being the most severe form, characterized by the absence of sperm in ejaculate due to testicular failure. According to the World Health Organization (WHO), infertility affects 15% of couples worldwide, with male factors contributing to about 50% of cases. NOA accounts for 10-15% of infertile men and is associated with genetic abnormalities, hormonal imbalances, and environmental factors. The condition has significant psychological and social impacts, and current treatment options, such as testicular sperm extraction (TESE), have limited success rates. Research into the molecular mechanisms underlying NOA is crucial for developing targeted therapies and improving reproductive outcomes.

Non-obstructive azoospermia is an ideal model for studying spermatogenesis and testicular function due to its well-defined clinical phenotype and the availability of testicular biopsies for molecular analysis. Key research areas include:

• • Identification of genetic mutations causing NOA (e.g., in genes like DAZL, SYCP3, and TEX11).
• • Understanding the role of Sertoli cells and germ cell interactions.
• • Investigating epigenetic modifications and non-coding RNAs in spermatogenesis.
• • Developing in vitro models to study spermatogonial stem cell differentiation.

Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas, provide valuable resources for studying gene expression in testicular tissues. However, many open questions remain, including the functional consequences of specific mutations and the development of targeted therapies.

While male infertility is not a cancer, the molecular pathways involved in spermatogenesis share similarities with cell proliferation and differentiation pathways. Key pathways include:

1. PI3K/AKT signaling: Regulates germ cell survival and proliferation. Dysregulation leads to apoptosis and impaired spermatogenesis.

2. MAPK/ERK pathway: Involved in Sertoli cell function and blood-testis barrier integrity. Aberrant activation disrupts spermatogenesis.

3. Wnt/β-catenin signaling: Critical for spermatogonial stem cell self-renewal. Mutations in Wnt pathway components cause spermatogenic arrest.

4. TGF-β/BMP signaling: Regulates Sertoli cell proliferation and differentiation. Disruption leads to testicular dysgenesis.

Data from ClinVar and COSMIC databases.

Key signaling networks involved in NOA:

• • PI3K/AKT/mTOR: Regulates germ cell survival. Mutations in PTEN or PI3K lead to apoptosis.
• • MAPK/ERK: Controls Sertoli cell tight junctions. Dysregulation disrupts blood-testis barrier.
• • Wnt/β-catenin: Maintains spermatogonial stem cell pool. Overactivation leads to premature differentiation.
• • TGF-β/BMP: Modulates Sertoli cell proliferation. Aberrant signaling causes testicular atrophy.

These networks are potential therapeutic targets for restoring spermatogenesis.

Organoids derived from testicular cells offer a more physiologically relevant model for studying spermatogenesis. They recapitulate the seminiferous tubule structure and support germ cell differentiation.

• • Genetically engineered mouse models (GEMMs): Knockout mice for DAZL, SYCP3, and TEX11 exhibit azoospermia, providing valuable in vivo models.
• • Chemically induced models: Administration of busulfan or radiation induces spermatogenic failure.
• • Patient-derived xenografts (PDX): Testicular tissue from NOA patients can be xenografted into immunodeficient mice to study spermatogenesis.
• • In vitro spermatogenesis models: Organ culture systems that support spermatogonial differentiation.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific mutations associated with NOA. For example:

• • DAZL knockout Sertoli cell lines: To study the role of DAZL in germ cell support.
• • SYCP3 knock-in cell lines: Introducing a missense mutation to model meiotic defects.
• • TEX11 knockout spermatogonial cell lines: To investigate meiotic recombination.

These models are commercially available and sequence-verified, providing reproducible tools for functional studies. They are essential for validating genetic variants identified in patient cohorts and for drug screening.

Gene-edited cell lines allow researchers to validate the functional impact of genetic variants associated with NOA. For example:

• • Knockout of DAZL in Sertoli cells leads to reduced expression of spermatogenesis-related genes, confirming its role.
• • Knock-in of SYCP3 mutation results in defective synaptonemal complex formation, as observed in patients.
• • CRISPR screens can identify novel genes essential for spermatogenesis by systematically knocking out genes in spermatogonial cell lines.

Isogenic cell line pairs (wild-type vs. mutant) are powerful tools for drug screening. For instance:

• • Screening compounds that rescue spermatogenesis in DAZL knockout cells.
• • Testing drugs that modulate the PI3K/AKT pathway to promote germ cell survival.
• • Modeling resistance to chemotherapy-induced infertility by introducing protective mutations.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in cells with specific NOA mutations. This approach can reveal novel therapeutic targets and biomarkers for early diagnosis.